Acupath Laboratories, Inc. now offers the BioFire® FilmArray® Gastrointestinal Pathogen (GI) Panel, a PCR based molecular infectious disease test from stool.

At present, this is the largest FDA approved, broad based test panel to reach the market. With the initial test, it is more likely that your infectious disease will be isolated and diagnosed so proper treatment can be initiated for your patient.

The BioFire GI Panel is capable of simultaneous detection and identification of multiple bacteria, viruses, and parasites from individuals with signs and/or symptoms of gastrointestinal infection. The BioFire GI Panel is a PCR based qualitative multiplexed in vitro diagnostic test.

BioFire GI Panel. 1 Test. 22 Pathogens.

98.5% sensitivity and 99.2% specificity1

Sample Requirements

0.2 mL stool in Cary Blair transport medium

Run Time

~1 hour

Who to Test

Individuals at high risk of spreading disease to others and during known or suspected outbreaks.3

Patients presenting with: 2,3
  • Dysentery
  • Diarrhea with fever, severe abdominal cramps, or signs of sepsis
  • Moderate to severe disease
  • Symptoms lasting more than seven days
  • Immunocompromised patients with diarrhea
Identify What Traditional Testing Is Missing.

The BioFire GI Panel provides greater sensitivity and range of detection by identifying an average of 25%-36% more possible pathogens vs traditional testing.4,6,7

Better Testing. Better Care.

A recent study demonstrated clinicians made timelier and pathogen directed patient management decisions with increased targeted therapy with the use of the BioFire GI Panel compared to traditional testing.4

Cut Unneeded Downstream Procedures.

Patients were shown to be 12.5% less likely to undergo endoscopy and 7.3% less likely to receive abdominal imaging vs traditional testing.5

Help Your Patient Receive Rapid Treatment.

Avoid the result delays of 5-10 days with traditional cultures.

Get results within 24 Hours from receipt of the specimen in the laboratory.

The stated performance is the aggregate of the prospective data from the clinical study. 2. Shane A, et al. (2017) Clin Infect Dis. 65(12): 45. 3. Riddle M, et al. (2016) Am J Gastroenterol. 111(5): 602. 4. Cybulski R, et al. (2018) Clin Infect Dis. 67(11): 1688. 5. Axelrad J, et al. (2019) J Clin Microbiol. 57(3): 01775. 6. Beal S, et al. (2018) J Clin Microbiol. 56(1): 01457. 7. Spina A, et al. (2015) Clin Microbiol Infect. 21(8): 719.

The New Acupath
Reinvented, Reimagined, Rediscovered


CONTACT USQuestions?

    Name (required)*

    Email (required)*

    Phone Number (required)*